

TRANSACTIONS GRANTED EARLY TERMINATION BETWEEN: 041095 AND 042195—Continued

Name of acquiring person, name of acquired person, name of acquired entity	PMN No.	Date terminated
Arch Communications Group, Inc., USA Mobile Communications Holdings, Inc., USA Mobile Communications Holdings, Inc.	95-1420	04/21/95
Citizens, Inc., American Liberty Financial Corporation, American Liberty Financial Corporation	95-1433	04/21/95
Living Centers of America, Inc., Mr. Donald C. Beaver, see attached list	95-1435	04/21/95
Mr. Donald C. Beaver, Living Centers of American, Inc. Living Centers of America, Inc.	95-1436	04/21/95
Akzo Nobel nv, BASF Aktiengesellschaft ("BASF AG"), BASF Corporation	95-1437	04/21/95
The Dow Chemical Company, Oasis Pipe Line Company, Oasis Pipe Line Company	95-1440	04/21/95
Egyptian General Petroleum Corporation, Mosvold Shipping AS, Seadrill 97, Inc.	95-1441	04/21/95
Coastal Healthcare Group, Inc., Mid-South Insurance Company, Mid-South Insurance Company	95-1442	04/21/95
Oxford Health Plans, Inc., OakTree Health Plan, Inc., OakTree Health Plan, Inc.	95-1443	04/21/95
Tiger (a limited partnership), XTRA Corporation, XTRA Corporation	95-1444	04/21/95
Panther Partners L.P., XTRA Corporation, XTRA Corporation	95-1445	04/21/95
Puma (a limited partnership), EXTRA Corporation, XTRA Corporation	95-1446	04/21/95
USA Mobile Communications Holdings, Inc., Arch Communications Group, Inc., Arch Communications Group, Inc.	95-1447	04/21/95
ABC Rail Products Corporation, General Electric Corp., GE Railcar Wheel	95-1448	04/21/95
AMP Incorporated, M/A-Com, Inc., M/A-Com, Inc.	95-1449	04/21/95
The Jaguar Fund N.V., XTRA Corporation, XTRA Corporation	95-1450	04/21/95
Union Pacific Corporation, Robert M. Edsel, Gemini Exploration Company	95-1451	04/21/95
International Reality Investors, L.L.C., Bramalea Inc., Colonial Park Mall	95-1454	04/21/95
RIT Capital Partners PLC, Mr. David Elias, H-G Holdings, Inc.	95-1456	04/21/95
The Coastal Corporation, Cohyco, Inc., Maverick Markets, Inc.	95-1457	04/21/95
Golder, Thoma, Cressey, Rauner Fund IV, L.P., Kwik-Wash Laundries, Inc., Ford Coin Laundries, Inc.	95-1458	04/21/95
Kelso Investment Associates V, L.P., Peebles Inc., Peebles Inc.	95-1459	04/21/95
Converse Inc., Apex One, Inc., Apex One, Inc.	95-1461	04/21/95
Code, Hennessy & Simmons II, L.P., Home-Crest Corporation, Home-Crest Corporation	95-1462	04/21/95
Elcat, Inc., Chattem, Inc., Chattem Chemicals Division	95-1465	04/21/95
Roland O. Perelman, Stephen J. Cannell, Cannell Entertainment, Inc.	95-1470	04/21/95
Clal (Israel) Ltd., Pharmaceutical Resources, Inc., Pharmaceutical Resources, Inc.	95-1471	04/21/95

FOR FURTHER INFORMATION CONTACT:

Sandra M. Peay or Renee A. Horton, Contact Representatives, Federal Trade Commission, Premerger Notification Office, Bureau of Competition, room 303, Washington, DC 20580 (202) 326-3100.

By Direction of the Commission.

Donald S. Clark,

Secretary.

[FR Doc. 95-10885 Filed 5-2-95; 8:45 am]

BILLING CODE 6750-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 95N-0108]

Drug Export; VAQTA™ Hepatitis A Vaccine, Purified Inactivated

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Merck & Co., Inc., has filed an application requesting approval for the export of the final bulk human biological product VAQTA™ Hepatitis A Vaccine, Purified Inactivated to the

Federal Republic of Germany and The United Kingdom.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of human biological products under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT:

Cathy Conn, Center for Biologics Evaluation and Research (HFM-610), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, 301-594-1070.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of biological products that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section

802(b)(3)(A) of the act requires that the agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Merck & Co., Inc., P.O. Box 4, West Point, PA 19486, has filed an application requesting approval for the export of the final bulk human biological product VAQTA™ Hepatitis A Vaccine, Purified Inactivated, to the United Kingdom for filling into syringes and export to the Federal Republic of Germany and the United Kingdom. The VAQTA™ Hepatitis A Vaccine, Purified Inactivated, is a highly purified inactivated whole virus vaccine derived from hepatitis A virus grown in cell culture in human fibroblasts. The application was received and filed in the Center for Biologics Evaluation and Research on February 13, 1995, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets

Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by May 15, 1995, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Biologics Evaluation and Research (21 CFR 5.44).

Dated: April 12, 1995.

James C. Simmons,

Acting Director, Office of Compliance, Center for Biologics Evaluation and Research.

[FR Doc. 95-10898 Filed 5-2-95; 8:45 am]

BILLING CODE 4160-01-F

Health Care Financing Administration

[HSQ-227-N]

Medicare Program; Peer Review Organization Contracts: Solicitation of Statements of Interest From In-State Organizations—Alaska, Delaware, the District of Columbia, Idaho, Kentucky, Maine, Nebraska, Nevada, South Carolina, Vermont, and Wyoming

AGENCY: Health Care Financing Administration (HCFA), HHS.

ACTION: General notice.

SUMMARY: This notice, in accordance with section 1153(i) of the Social Security Act, announces the scheduled expiration dates of the current contracts between HCFA and several out-of-State Utilization and Quality Control Peer Review Organizations. It also specifies the period of time in which in-State organizations may submit a statement of interest so that they may be eligible to compete for these contracts. The States currently affected and their respective expiration dates are as follows:

Delaware	March 31, 1996.
Nevada	March 31, 1996.
Wyoming	March 31, 1996.
Alaska	June 30, 1996.
District of Columbia	June 30, 1996.
Idaho	June 30, 1996.
Maine	June 30, 1996.
Vermont	June 30, 1996.
Nebraska	September 30, 1996.
Kentucky	September 30, 1996.
South Carolina	September 30, 1996.

DATES: Written statements of interest must be received at the address

specified no later than 5 p.m. EST, June 2, 1995. Due to staffing and resource limitations, we cannot accept statements submitted by facsimile (FAX) transmission.

ADDRESSES: Statements of interest must be submitted to—Health Care Financing Administration, OFHR, OAG, Attn.: Brian Hebbel, Room G-M-1, East Low Rise Building, 6325 Security Boulevard, Baltimore, Maryland 21207.

FOR FURTHER INFORMATION CONTACT: Kathleen Kelso, (410) 966-7214.

SUPPLEMENTARY INFORMATION:

I. Background

The Peer Review Improvement Act of 1982 (Title I, Subtitle C of the Tax Equity and Fiscal Responsibility Act of 1982 (TEFRA), Pub. L. 97-248) amended Part B of Title XI of the Social Security Act (the Act) by establishing the Utilization and Quality Control Peer Review Organization (PRO) program. Congress created the PRO program in order to redirect, simplify, and enhance the cost-effectiveness and efficiency of the peer review process.

PROs currently review certain health care services furnished under Title XVIII of the Act (Medicare) and under certain other Federal programs to determine whether those services are reasonable, medically necessary, furnished in the appropriate setting, and are of a quality that meets professionally recognized standards. PRO activities are a part of the Health Care Quality Improvement Program (HCQIP) that supports HCFA's mission of assuring health care security for its eligible beneficiaries. The HCQIP is carried out locally by the PRO in each State. Under the HCQIP, PROs provide information for health care plans, providers, and practitioners to improve the quality of care furnished to Medicare beneficiaries.

In June 1984, HCFA began awarding contracts to PROs. We currently maintain 53 PRO contracts with organizations that provide medical review activities for 49 of the United States, the District of Columbia, Puerto Rico, and the Virgin Islands. The organizations that are eligible to contract as PROs have satisfactorily demonstrated that they are either physician-sponsored or physician-access organizations in accordance with sections 1152 and 1153 of the Act and our regulations at 42 CFR 462.102 and 462.103. A physician-sponsored organization is one that is both composed of a substantial number of the licensed doctors of medicine or osteopathy practicing medicine or surgery in the respective review area

and is representative of the physicians practicing in the review area. A physician-access organization is one that has available to it, by arrangement or otherwise, the services of a sufficient number of licensed doctors of medicine or osteopathy practicing medicine or surgery in the review area to assure adequate peer review of the services furnished by the various medical specialties and subspecialties. In addition, the organization must not be a health care facility, health care facility association, or a health care facility affiliate, and must have a consumer representative on its governing board.

The Omnibus Budget Reconciliation Act of 1987 (Pub. L. 100-203) amended section 1153 of the Act by adding a new subsection (i) that prohibits the Secretary from renewing the contract of any PRO that is not an in-State organization without first publishing in the **Federal Register** a notice announcing when the contract will expire. This notice must be published no later than 6 months before the date of expiration, and must specify the period of time during which an in-State organization may submit a proposal for the contract. If one or more qualified in-State organizations submits a proposal within the specified period of time, HCFA may not automatically renew the contract on a noncompetitive basis but must instead provide for competition for the contract in the same manner used for a new contract. An in-State organization is defined as an organization that has its primary place of business in the State in which review will be conducted or that is owned by a parent corporation, the headquarters of which is located in that State.

There are currently 11 PRO contracts with entities that do not meet the statutory definition of an in-State organization. The areas affected for purposes of this notice are Alaska, Delaware, the District of Columbia, Idaho, Kentucky, Maine, Nebraska, Nevada, South Carolina, Vermont, and Wyoming.

II. Provisions of the Notice

This notice announces the scheduled expiration dates of the current contracts between HCFA and the out-of-State PROs responsible for review in Alaska, Delaware, the District of Columbia, Idaho, Kentucky, Maine, Nebraska, Nevada, South Carolina, Vermont, and Wyoming. Interested in-State organizations may submit statements of interest to be the PRO for the aforementioned States. The statements must be received by HCFA no later than June 2, 1995. In its statement of interest, the organization must furnish materials